These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 30265523)

  • 41. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A brief history of antibody-based therapy.
    Alpaugh M; Cicchetti F
    Neurobiol Dis; 2019 Oct; 130():104504. PubMed ID: 31216439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: Insights and challenges.
    Wu H; Zhang T; Li N; Gao J
    J Control Release; 2023 Aug; 360():169-184. PubMed ID: 37343724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diffusion of macromolecules in the brain: implications for drug delivery.
    Wolak DJ; Thorne RG
    Mol Pharm; 2013 May; 10(5):1492-504. PubMed ID: 23298378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanocarrier-mediated curcumin delivery: An adjuvant strategy for CNS disease treatment.
    Godse S; Zhou L; Sakshi S; Singla B; Singh UP; Kumar S
    Exp Biol Med (Maywood); 2023 Nov; 248(22):2151-2166. PubMed ID: 38058006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New immunological approaches in treating and diagnosing CNS diseases.
    Guo K; Janigro D
    Pharm Pat Anal; 2013 May; 2(3):361-71. PubMed ID: 24237062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies.
    Padmakumar S; D'Souza A; Parayath NN; Bleier BS; Amiji MM
    J Control Release; 2022 Dec; 352():121-145. PubMed ID: 36252748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioinspired Approaches for Central Nervous System Targeted Gene Delivery.
    Kumar J; Karim A; Sweety UH; Sarma H; Nurunnabi M; Narayan M
    ACS Appl Bio Mater; 2024 Aug; 7(8):4975-4997. PubMed ID: 38100377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.
    Carpanini SM; Torvell M; Morgan BP
    Front Immunol; 2019; 10():362. PubMed ID: 30886620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
    Crawford L; Rosch J; Putnam D
    J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical applications involving CNS gene transfer.
    Kantor B; McCown T; Leone P; Gray SJ
    Adv Genet; 2014; 87():71-124. PubMed ID: 25311921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current approaches to facilitate improved drug delivery to the central nervous system.
    Markowicz-Piasecka M; Darłak P; Markiewicz A; Sikora J; Kumar Adla S; Bagina S; Huttunen KM
    Eur J Pharm Biopharm; 2022 Dec; 181():249-262. PubMed ID: 36372271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The blood-brain barrier and nasal drug delivery to the central nervous system.
    Miyake MM; Bleier BS
    Am J Rhinol Allergy; 2015; 29(2):124-7. PubMed ID: 25785753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
    Meng J; Agrahari V; Youm I
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.
    Lathuilière A; Laversenne V; Astolfo A; Kopetzki E; Jacobsen H; Stampanoni M; Bohrmann B; Schneider BL; Aebischer P
    Brain; 2016 May; 139(Pt 5):1587-604. PubMed ID: 26956423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current approaches for drug delivery to central nervous system.
    Hossain S; Akaike T; Chowdhury EH
    Curr Drug Deliv; 2010 Dec; 7(5):389-97. PubMed ID: 20950269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.